Elsevier

Ophthalmology

Volume 120, Issue 6, June 2013, Pages 1186-1194
Ophthalmology

Original article
Ultrathin Descemet's Stripping Automated Endothelial Keratoplasty with the Microkeratome Double-Pass Technique: Two-Year Outcomes

Presented in part at: American Academy of Ophthalmology Annual Meeting, October 2010, Chicago, Illinois, and October 2011, Orlando, Florida.
https://doi.org/10.1016/j.ophtha.2012.11.030Get rights and content

Purpose

To evaluate the outcomes and graft survival rates after ultrathin (UT) Descemet's stripping automated endothelial keratoplasty (DSAEK) using the microkeratome-assisted double-pass technique.

Design

Prospective, consecutive, interventional case series.

Participants

Patients with endothelial decompensation of various causes (Fuchs endothelial dystrophy, pseudophakic or aphakic bullous keratopathy, failed previous graft, herpetic endotheliitis, or buphthalmus; n = 285 grafts).

Intervention

Donor preparation was performed using the microkeratome-assisted double-pass technique. Stripping of the Descemet's membrane was performed under air and the graft was delivered into the anterior chamber using the pull-through technique through a 3-mm clear-cornea incision using a modified Busin glide.

Main Outcome Measures

Best spectacle-corrected visual acuity (BSCVA), manifest refraction, endothelial cell density, and graft thickness (GT).

Results

Excluding all eyes with pre-existing ocular comorbidities, mean BSCVA at 3, 6, 12, and 24 months was 0.16, 0.11, 0.08, and 0.04 logarithm of the minimum angle of resolution units, respectively. The percentage of patients achieving BSCVA of 20/20 or better at 3, 6, 12, and 24 months was 12.3%, 26.3%, 39.5%, and 48.8%, respectively. A statistically significant (P < 0.0001) hyperopic shift of 0.78 ± 0.59 diopters (D; range, −0.75 to 1.75 D) was found at 1 year. The endothelial cell loss at 3, 6, 12, and 24 months was 29.8 ± 14.3%, 33 ± 15.5%, 35.6 ± 14.1%, and 36.6 ± 16.0%, respectively. The mean central GT recorded 3 months after surgery was 78.28 ± 28.89 μm. Complications included microkeratome failure to achieve perfect dissection in 21 donor tissues (7.2%), with 6 (2.1%) being discarded; total graft detachment in 11 cases (3.9%); primary failure in 4 cases (1.4%); and secondary failure in 4 additional cases (1.4%). Kaplan-Meier cumulative probability of a rejection episode at 3, 6, 12, and 24 months was 0%, 0.4%, 2.4%, and 3.3%, respectively.

Conclusions

The visual outcomes of UT DSAEK are comparable with those published for Descemet's membrane endothelial keratoplasty and better than those reported after DSAEK in terms of both speed of visual recovery and percentage of patients with 20/20 final visual acuity. However, unlike with Descemet's membrane endothelial keratoplasty, preparation and delivery of donor tissue are neither difficult nor time consuming. Complications of UT DSAEK do not differ substantially from those recorded with standard DSAEK but are much less frequent than those reported after Descemet's membrane endothelial keratoplasty.

Financial Disclosure(s)

Proprietary or commercial disclosure may be found after the references.

Section snippets

Patients and Methods

All consecutive patients operated on by the same surgeon (M.B.) using the microkeratome-assisted double-pass technique10 at Villa Serena-Villa Igea Private Hospitals, Forlì, Italy, from January 2010 through December 2011 were included in a prospective study aimed at evaluating the outcomes of this technique.

The study followed the tenets of the 1964 Declaration of Helsinki and was approved by the local ethics committee; detailed informed consent was provided by all patients undergoing UT DSAEK.

Results

Two hundred eighty-five UT DSAEK procedures performed in 279 eyes (6 repeat UT DSAEK procedures) of 250 patients were included in the study. Demographics and indications for surgery are shown in detail in Table 2 (available at http://aaojournal.org). An example of pseudophakic bullous keratopathy is shown in Figure 3A, B. All phakic patients with a perfectly clear crystalline lens underwent simple DSAEK, whereas even minimal lens changes in elderly patients (age >60 years) were sufficient to

Discussion

Many authors claim that final visual acuity after DSAEK is suboptimal, with fewer eyes than expected achieving 20/20 vision, possibly because of the presence of a stromal interface.1, 2, 3, 13 In comparison with most of the DSAEK series published to date, DMEK has shown a decisive improvement in terms of speed of visual recovery, percentage of patients achieving 20/20 vision, and rate of immunologic rejection.6, 7, 8 However, ease of graft preparation, manipulation, delivery, and attachment, as

References (28)

  • L. Ham et al.

    Endothelial cell density after Descemet membrane endothelial keratoplasty: 1- to 2-year follow-up

    Am J Ophthalmol

    (2009)
  • M.O. Price et al.

    Endothelial cell loss after Descemet stripping with endothelial keratoplasty: influencing factors and 2-year trend

    Ophthalmology

    (2008)
  • J.Y. Li et al.

    Graft rejection after Descemet stripping automated endothelial keratoplasty: graft survival and endothelial cell loss

    Ophthalmology

    (2012)
  • K.D. Neff et al.

    Comparison of central corneal graft thickness to visual acuity outcomes in endothelial keratoplasty

    Cornea

    (2011)
  • Cited by (183)

    • Efficacy of Thin and Ultrathin Descemet Stripping Automated Endothelial Keratoplasty and Influence of Graft Thickness on Postoperative Outcomes: Systematic Review and Meta-analysis

      2022, American Journal of Ophthalmology
      Citation Excerpt :

      The definition of UT-DSAEK grafts is also not consistent, varying from threshold under 10010,36 to 1307,49 µm of central graft thickness. In addition, studies referred either to the postoperative graft thickness108,109 or thickness immediately after cutting.7,9,29 In this meta-analysis, we considered thin DSAEK as DSAEK grafts <130 µm thick and ultrathin DSAEK grafts <100 µm thick,16 based on their preoperative thickness, to provide predictable results.

    View all citing articles on Scopus

    Manuscript no. 2012-973.

    Financial Disclosure(s): The author(s) have made the following disclosure(s): Massimo Busin - Travel and royalties - Moria

    The remaining authors have no financial interests to disclose.

    View full text